NasdaqCM - Nasdaq Real Time Price USD

VivoSim Labs, Inc. (VIVS)

0.1550 +0.0004 (+0.26%)

As of 9:44:24 AM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling

GlobeNewswire 12d ago

VIVS
+0.26%
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

GlobeNewswire 26d ago

VIVS
+0.26%
VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)

InvestorsHub 3mo ago

VIVS
+0.26%
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

GlobeNewswire 3mo ago

VIVS
+0.26%
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

GlobeNewswire 3mo ago

VIVS
+0.26%
VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth

InvestorsHub 3mo ago

VIVS
+0.26%
LLY
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

GlobeNewswire 3mo ago

VIVS
+0.26%
LLY
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

GlobeNewswire 4mo ago

VIVS
+0.26%
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing

GlobeNewswire 6mo ago

VIVS
+0.26%
VivoSim Announces Pricing of up to a $4 Million Public Offering

GlobeNewswire 6mo ago

VIVS
+0.26%
Top Midday Gainers

PREMIUM
MT Newswires 8mo ago

VIVS
+0.26%
SNDK

TCGL
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

GlobeNewswire 1mo ago

VIVS
+0.26%

Performance Overview

Return	VIVS	S&P 500 (^GSPC)
YTD	-91.46%	+10.73%
1-Year	-94.81%	+11.11%
3-Year	-98.77%	+81.91%

U.S. markets close in 6h 8m

VivoSim Labs, Inc. (VIVS)

VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth

VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing

VivoSim Announces Pricing of up to a $4 Million Public Offering

Top Midday Gainers

VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs